Delivery Order SPE2DR25D1102-SPE2DR26FFB2T
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,388.84 to supply Oseltamivir Phosphate 75 mg capsules in unit dose packages of 10 units. The order was competitively awarded with no set-aside designation and carries a firm fixed price structure with an ultimate completion date of December 19, 2025. AmerisourceBergen will perform this work from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on January 7, 2026, for the supply of Oseltamivir Phosphate 75 mg capsules in unit dose packaging (10s). The contract is valued at $14,926.77 with a completion date of January 8, 2026, and is structured as a firm fixed-price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is executed under...
- The Defense Logistics Agency awarded a delivery order valued at $8,540.43 to AmerisourceBergen Drug Corp for the supply of Oseltamivir Phosphate 75 mg capsules (100-count packaging) on January 13, 2026, with an ultimate completion date of January 14, 2026. This is a firm fixed-price contract with no set-aside designation, indicating open competition. The place of performance is located in Conshohocken, Pennsylvania, which serves as the company's corporate headquarters and pharmaceutical...
- The Defense Logistics Agency awarded a $4,007.79 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 7, 2026, for the supply of Oseltamivir Phosphate 75 mg capsules in unit dose packaging of 10 tablets. This contract, which is non-set-aside and competitively awarded, will be performed at the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of January 8, 2026. The delivery order is issued under AmerisourceBergen's parent...
- The Defense Logistics Agency awarded a delivery order valued at $2,684.75 to AmerisourceBergen Drug Corp for the supply of Oseltamivir Phosphate 75 mg capsules (100-count units) on January 6, 2026, with completion expected by January 7, 2026. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on January 21, 2026, for the supply of Oseltamivir Phosphate 75 mg capsules in unit dose packaging of 10s, with a ceiling value of $1,408.31. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is Conshohocken, Pennsylvania, with an ultimate completion date of January 22, 2026. AmerisourceBergen Drug Corp, a subsidiary of parent...
- The Defense Logistics Agency awarded a delivery order valued at $1,690.92 to AmerisourceBergen Drug Corp for Oseltamivir Phosphate 75 mg capsules (Unit Dose, 10-count) on January 7, 2026, with an ultimate completion date of January 8, 2026. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,246.76 to AmerisourceBergen Drug Corp for the supply of Oseltamivir Phosphate 75 mg capsules in unit dose packs of 10 on January 7, 2026, with an ultimate completion date of January 8, 2026. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's...
- The Defense Logistics Agency awarded a $4,994.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 7, 2026, for the supply of Oseltamivir Phosphate 75 mg capsules in unit dose packaging (10s). This is a non-set-aside competitive award with an ultimate completion date of January 8, 2026, and performance location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor serving federal...
- The Defense Logistics Agency awarded a $5,694.32 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Oseltamivir Phosphate 75 mg capsules in unit dose packaging (10-count) on December 2, 2025, with completion due by December 3, 2025. This competitive award, which received no set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DR25D1102Indefinite Delivery Contract
- SPE2DR25D1102-SPE2DR26FFB2TDelivery Order
The Defense Logistics Agency awarded a $7,890.62 delivery order to AmerisourceBergen Drug Corp on January 28, 2026, for the supply of Oseltamivir Phosphate 75 mg capsules in unit dose packages of 10. This competitively awarded, firm fixed-price contract carries no set-aside designation and is scheduled for completion by January 29, 2026. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a task order against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999.999 billion through December 2026, which serves as a comprehensive global pharmaceutical support vehicle enabling the supply of a broad range of medications and medical commodities to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc. (doing business as AmerisourceBergen), is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. The company maintains extensive experience fulfilling federal pharmaceutical requirements across multiple therapeutic domains and has consistently demonstrated capability to meet government procurement standards through competitive procurements. The oseltamivir supply under this order supports the Defense Health Agency and related military treatment facilities that depend on the DLA's medical supply chain for antiviral medications and related pharmaceutical commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.9k | 1/27/26 |